Official Title
Treatment of COVID-19 Patients Using Wharton's Jelly-Mesenchymal Stem Cells
Brief Summary

The purpose of this study is to investigate the potential use of Wharton's Jelly Mesenchymal stem cells (WJ-MSCs) for treatment of patient diagnosed with Corona Virus SARS-CoV-2 infection, and showing symptoms of COVID-19.

Detailed Description

COVID-19 is a condition caused by infection with Coronoa Virus (SARS-CoV-2). This virus has a high transmission rate and is spreading at very high rates. causing a worldwide pandemic. Patients diagnosed with COVID-19 and confirmed positive with the virus, will be given three IV doses of WJ-MSCs consisting of 1X10e6/kg. The three doses will be 3 days apart form each other.

Patients will be followed up for a period of three weeks to assess the severity of the condition and measure the viral titers.

Use of Stem Cells for COVID-19 Treatment

Biological: WJ-MSCs
WJ-MSCs will be derived from cord tissue of newborns, screened for HIV1/2, HBV, HCV, CMV, Mycoplasma, and cultured to enrich for MSCs.
WJ-MSCs will be counted and suspended in 25 ml of Saline solution containing 0.5% human serum Albumin, and will be given to patient intravenously.

Eligibility Criteria

Inclusion Criteria:

COVID-19 positive according to diagnosis and clinical management of COVID-19 criteria.

Exclusion Criteria:

- Participants in other clinical trials

- patients with malignant tumors

- pregnant and lactating women

- co-infection with other infectious viruses or bacteria

- History of several allergies

- Patients with history of pulmonary embolism

- any liver or kidney diseases

- HIV positive patients

- Considered by researchers to be not suitable to participate in this clinical trial

- Chronic heart failure with ejection fraction less than 30%.

Eligibility Gender
Eligibility Age
Minimum: 18 Years

Adeeb M AlZoubi, Ph.D.

Ahmad Y AlGhadi, M.Sc.

Stem Cells Arabia
NCT Number
stem cells